Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

New hope in global fight against antibiotic resistant superbugs

January 22, 2021May 19, 2021 Alterity Therapeutics

New hope in global fight against antibiotic resistant superbugs

Post navigation

Alterity participates in world’s largest virtual healthcare conference JP Morgan

Quarterly Cash Flow Report

Related Posts

Prana drug treatment PBT2 named one of Top Neuroscience Projects to Watch

September 4, 2013

Quarterly Cash Flow Report

October 30, 2019October 30, 2019

Prana Announces A$6.0 Million Capital Raising

July 17, 2013

Recent Posts

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
Alterity to Present at Life Sciences Investor Forum
Alterity Therapeutics to Present at the GCFF Virtual Conference 2022 – Investing in Healthcare
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065